The ASCO Post

🩸 Biomarker testing continues to shape the future of immuno-oncology.

New findings evaluating tissue-based and blood-based TMB testing raise important questions about:
• Predicting immunotherapy benefit
• Selecting the right patients for treatment
• The evolving role of liquid biopsy technologies

An important discussion as precision oncology continues to advance.

Presented by Suneel Kamath, MD of Cleveland Clinic Cancer Institute at .

https://ascopost.com/news/june-2026/does-tissue-tmb-outperform-blood-based-testing-for-predicting-immunotherapy-response/

New data support expanding the conversation around treatment options for early-stage hepatocellular carcinoma (HCC).

In the largest, multinational patient-level analysis to date, external-beam radiation therapy (EBRT) achieved survival outcomes comparable to surgical resection, thermal ablation, and other ablative therapies.

Findings like these may help inform multidisciplinary treatment planning and broaden consideration for EBRT in appropriate patients.

Study by Maria Reig, MD, PhD of Barcelona University; Published in Journal of Clinical Oncology by ASCO

https://ascopost.com/news/june-2026/overall-survival-with-ebrt-in-hepatocellular-carcinoma/

New findings from the phase III ASCENT-04 trial may help redefine first-line treatment for PD-L1–positive metastatic triple-negative breast cancer.

Sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival 2 (PFS2) compared with chemotherapy plus pembrolizumab, providing further evidence for the potential of antibody-drug conjugate and immunotherapy combinations.

Presented by Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University at

https://ascopost.com/news/june-2026/sacituzumab-govitecan-with-pembrolizumab-extends-pfs2-in-pd-l1-positive-metastatic-triple-negative-breast-cancer/

A major step forward for precision medicine in early breast cancer.

New phase III data show that test-guided chemotherapy decision-making was noninferior to standard approaches, supporting the use of genomic testing to help identify which patients may safely avoid chemotherapy without compromising outcomes.

Advances like these continue to move oncology toward more personalized treatment strategies.

Presented by Rob Stein, MA, MB BChir, PhD, FRCP of UCL Cancer Institute, and Iain MacPherson, MD, PhD, FRCP, of Institute of Cancer Sciences at the University of Glasgow at

https://ascopost.com/news/june-2026/phase-iii-trial-shows-noninferiority-for-test-guided-chemotherapy-decisions-in-early-breast-cancer/

As generative AI becomes more accessible, patients and caregivers are increasingly turning to these tools for cancer-related information.

In this discussion, Rashad Ismayilov, MD, of Baskent University, and Ravi Parikh, MD, MPP, FACP, of Emory University and the Editor-in-Chief of ASCO AI in Oncology, review findings on how patients and caregivers are using generative AI tools, offering valuable insights into adoption patterns, trust, and experiences of patients with cancer and caregivers seeking cancer information.

Understanding how patients engage with AI may be just as important as clinicians understanding the technology.

https://ascoai.org/videos/newsreels/2026/patient-and-caregiver-usage-of-generative-ai-tools-for-cancer-information-in-turkey/

Cancer screening innovation continues to evolve, and so does our understanding of its impact.

Results from the first randomized trial of the Galleri multicancer early detection (MCED) test showed a reduction in stage IV cancer diagnoses, although the study did not meet its primary endpoint.

Key takeaway:
➡️ Fewer late-stage cancer diagnoses
➡️ Important new evidence for MCED screening
➡️ Continued questions about implementation and clinical utility

Presented by Charles Swanton, MD, PhD, of The Francis Crick Institute and University College London Cancer Institute at

https://ascopost.com/news/june-2026/annual-galleri-screening-reduced-stage-iv-cancer-diagnoses-but-missed-primary-endpoint-in-first-randomized-mced-trial

The latest issue of The ASCO Post is now available, featuring some of the most impactful research and clinical updates emerging from and , as well as perspectives on a cervical cancer program in Haiti, geriatric assessments, colorectal cancer prevention, cannabis use and cancer impact, and on the paradigm-shifting pancreatic cancer data from the ASCO Annual Meeting.

Highlights include:
• Practice-changing advances in pancreatic cancer
• New developments in breast and lung cancer treatment
• Progress in precision oncology and biomarker-driven care
• Expert perspectives on emerging standards of care

Explore the new issue: https://ascopost.com/issues/june-10-2026/

We extend our sincere gratitude to the outstanding members of The ASCO Post Editorial Board for their leadership, expertise, and unwavering commitment to advancing oncology education and communication. Their guidance has been instrumental in helping establish The ASCO Post as a trusted source of timely, authoritative cancer news and clinical insights for the global oncology community.

We also recognize the exceptional contributions of our editorial team, whose dedication to delivering comprehensive coverage of the latest research, policy developments, and practice-changing advances continues to support oncology professionals worldwide.

Today, The ASCO Post is widely regarded as one of the most-read oncology publications, reaching clinicians, researchers, and cancer care professionals around the world. We are deeply grateful to our readers, contributors, and supporters for their continued engagement and partnership in our shared mission to improve cancer care through education and information.

We're grateful for the leadership and insights of The ASCO Post Editorial Board. Featured below some of our Editorial Board; see the full list of Editorial Advisors who help shape our content: https://ascopost.com/editorial-board/

Advances in aggressive B-cell lymphomas continue to build on the foundation of R-CHOP.

New research suggests that combining targeted immunotherapies with standard R-CHOP may significantly delay disease progression, offering a promising strategy to improve outcomes in patients with aggressive lymphoma.

A strong development in the evolving treatment landscape for B-cell malignancies.

Presented by Georg Lenz, MD, of University Hospital Münster at

https://ascopost.com/news/june-2026/combining-targeted-immunotherapies-with-standard-r-chop-delays-progression-of-aggressive-b-cell-lymphomas/

Large cancer databases like Surveillance, Epidemiology, and End Results (SEER) play a critical role in shaping oncology research, policy, and clinical understanding.

New findings suggesting potential missing patient information underscore the importance of data accuracy and completeness in real-world evidence generation.

An important conversation for researchers, clinicians, and healthcare leaders.

Study by Schelomo Marmor, PhD, MPH of University of Minnesota Twin Cities, and McKenzie White, MD of Moffitt Cancer Center Published in American College of Surgeons

https://ascopost.com/news/may-2026/study-shows-potential-missing-patient-information-in-seer-database/